PDL BioPharma, Inc. Working Capital

Working Capital of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending June 29, 2020 was $459 Million (a -9.85% decrease compared to previous quarter)
  • Year-over-year quarterly Working Capital increased by 25.51%
  • Annual Working Capital for 2019 was $268 Million (a -42.29% decrease from previous year)
  • Annual Working Capital for 2018 was $465 Million (a 3.89% increase from previous year)
  • Annual Working Capital for 2017 was $447 Million (a 67.09% increase from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of PDL BioPharma, Inc.

Most recent Working Capitalof PDLI including historical data for past 10 years.

Interactive Chart of Working Capital of PDL BioPharma, Inc.

PDL BioPharma, Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $459.31 $509.51
2019 $268.2 $365.96 $361.37 $434.23 $268.2
2018 $464.75 $461.08 $462.95 $459.98 $464.75
2017 $447.33 $419.1 $260.52 $268.77 $447.33
2016 $267.72 $233.54 $298.1 $348.24 $267.72
2015 $245.97 $212.1 $223.15 $157.92 $245.97
2014 $167.91 $79.8 $-78.37 $10.63 $167.91
2013 $-299.73 $123.66 $46.73 $189.92 $-299.73
2012 $172.51 $170.58 $144.33 $56.56 $172.51
2011 $100.51 $44.63 $-4.59 $-161.57 $100.51
2010 $90.67 $26.09 $-66.48 $90.67

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.